دورية أكاديمية
Effectiveness of rotavirus pentavalent vaccine under a universal immunization programme in Israel, 2011-2015: a case-control study.
| العنوان: | Effectiveness of rotavirus pentavalent vaccine under a universal immunization programme in Israel, 2011-2015: a case-control study. |
|---|---|
| المؤلفون: | Muhsen K; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University Ramat Aviv, Tel Aviv, Israel. Electronic address: kmuhsen@post.tau.ac.il., Anis E; Division of Epidemiology, Ministry of Health, Jerusalem, Israel., Rubinstein U; Department of Pediatrics, Laniado Medical Center, Netanya, Israel., Kassem E; Department of Pediatrics, Hillel Yaffe Medical Center, Hadera, Israel., Goren S; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University Ramat Aviv, Tel Aviv, Israel., Shulman LM; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University Ramat Aviv, Tel Aviv, Israel; Central Virology Laboratory, Ministry of Health, Tel Hashomer, Israel., Ephros M; Department of Pediatrics, Carmel Medical Center, Haifa, Israel; Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel., Cohen D; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University Ramat Aviv, Tel Aviv, Israel. |
| المصدر: | Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases [Clin Microbiol Infect] 2018 Jan; Vol. 24 (1), pp. 53-59. Date of Electronic Publication: 2017 Apr 22. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: England NLM ID: 9516420 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1469-0691 (Electronic) Linking ISSN: 1198743X NLM ISO Abbreviation: Clin Microbiol Infect Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2015- : London : Elsevier Original Publication: Paris : Decker Europe, c1995- |
| مواضيع طبية MeSH: | Gastroenteritis/*prevention & control , Immunization Programs/*statistics & numerical data , Rotavirus Infections/*prevention & control , Rotavirus Vaccines/*immunology, Case-Control Studies ; Child, Preschool ; Chromatography, Affinity ; Female ; Gastroenteritis/virology ; Hospitalization/statistics & numerical data ; Humans ; Infant ; Israel ; Male ; Rotavirus/immunology ; Rotavirus Infections/diagnosis ; Rotavirus Vaccines/therapeutic use ; Vaccination ; Vaccines, Attenuated/immunology ; Vaccines, Attenuated/therapeutic use |
| مستخلص: | Objectives: The use of rotavirus pentavalent vaccine (RotaTeq ® ) as a sole vaccine within rotavirus universal immunization programmes remains limited. We examined the effectiveness of RotaTeq in preventing rotavirus gastroenteritis (RVGE) hospitalization in Israel, after the introduction of universal immunization against the disease. Methods: A test-negative case-control study included age-eligible children for universal RotaTeq immunization (aged 2-59 months, born in 2011-2015). Cases (n = 98) were patients who tested positive for rotavirus by immunochromatography; those who tested negative (n = 628) comprised the control group. Information on rotavirus immunization history was obtained through linkage with a national immunization registry. Vaccination status was compared between cases and controls, adjusted odds ratios (aORs) were obtained from logistic regression models, and vaccine effectiveness calculated as (1 - aOR)*100. Results: Immunization with RotaTeq was less frequent in RVGE cases (73.5%) than in controls (90.1%), p < 0.001; this association persisted after controlling for potential confounders. Effectiveness of the complete vaccine series was estimated at 77% (95% confidence interval (CI): 49-90) in children aged 6-59 months, and 86% (95% CI: 65-94) in children aged 6-23 months; whereas for the incomplete series, the respective estimates were 72% (95% CI: 28-89) and 75% (95% CI: 30-91). Vaccine effectiveness was estimated at 79% (95% CI: 45-92) against G1P[8]-associated RVGE hospitalizations and 69% (95% CI: 11-89) against other genotype-RVGE hospitalizations. Conclusions: High effectiveness of RotaTeq as the sole rotavirus vaccine in a universal immunization programme was demonstrated in a high-income country. Although partial vaccination conferred protection, completing the vaccine series is warranted to maximize the benefit. (Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Effectiveness; Gastroenteritis; Post-marketing; Rotavirus; Vaccine |
| المشرفين على المادة: | 0 (RotaTeq) 0 (Rotavirus Vaccines) 0 (Vaccines, Attenuated) |
| تواريخ الأحداث: | Date Created: 20170427 Date Completed: 20180806 Latest Revision: 20181202 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1016/j.cmi.2017.04.018 |
| PMID: | 28442435 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!